Citations

Clear

20 citation(s) found for "Subash, C".

Efficacy and safety of TACE combined with immune checkpoint inhibitors and VEGF inhibitors in hepatocellular carcinoma: A systematic review and meta-analysis.
Vel, Adarsh, S, Noorul Hidhaya, Srinivasan, Gurunathan, Mariappan, Tejaswin , Radhakrishnan, Pranav Krishna, Saravanan, Shivani, Ganesan, Subash, Sundararajan, Sakthibalan, Velusamy, Breethiga, Mohanraj, Aswin Prabhu, Ritvika, Kalidindi, Nagarajan, Hrithik Dakssesh Putta, Kamaraj, Balakrishnan, S, Noorul Hidhaya, Srinivasan, Gurunathan, Nagarajan, Hrithik Dakssesh Putta , Kamaraj, Balakrishnan

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16300 Get It

e16300 Background: Transarterial chemoembolization (TACE) remains the standard of care for intermediate stage hepatocellular carcinoma (HCC), yet long term survival is limited by high rates of recurrence and progression. The addition of immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) with TACE has recently emerged as a promising strategy. This meta-analysis evaluates the efficacy and safety of TACE plus systemic combination therapy compared to TACE alone. Methods: A systematic review and meta-analysis was conducted according to PRISMA guidelines. Studies evaluating TACE combined with dual systemic therapy (ICI + TKI/VEGF inhibitor) were identified through major databases up to January 2026. Pooled odds ratios (ORs) and Hazards Ratio (HRs) were calculated using fixed effects models as appropriate. Results: Five studies (4 RCTs, 1 cohort) comprising 1964 patients were included. Progression-free survival was significantly longer with TACE combined with dual systemic therapy compared with TACE alone (mean difference 4.12 months, 95% CI 2.86-5.37; p < 0.00001; I² = 73%). The objective response rate was also significantly higher with TACE combination therapy (OR 2.66, 95% CI 2.17-3.26; p < 0.00001), despite substantial heterogeneity (I² = 83%). Grade 3/4 adverse events were significantly more frequent with TACE combination therapy (OR 3.36, 95% CI 2.66-4.25; p < 0.00001; I² = 68%). The most common severe toxicities included Hypertension (16.2%), Immune-mediated Hepatitis (9.6%), and Proteinuria (8.8%). Hypertension occurred significantly more often with TACE combination therapy than with TACE alone (pooled OR 9.52, 95% CI 1.83-49.62; p = 0.007; I² = 51%). Conclusions: The addition of ICI and TKI/VEGF inhibitors to TACE provides consistent, statistically significant and clinically meaningful improvement in disease control for unresectable HCC. This can be explained on the basis of complementary biological mechanisms, including enhanced tumor antigen exposure following TACE, restoration of antitumor T cell activity with ICI, and suppression of TACE induced angiogenesis through VEGF pathway blockade. While the efficacy benefit is robust across trials, safety profiles vary significantly by regimen.The higher rate of grade ¾ adverse effects, especially hypertension and immune-mediated hepatitis, is mainly due to the biological effects of VEGF inhibitors on blood vessels and the increased immune activation caused by immune checkpoint inhibitors. Despite a higher incidence of grade 3/4 toxicities, adverse events were generally manageable with standard supportive care and dose modifications. Overall, these findings support the use of TACE-systemic combinations as a new potential standard of care, with careful patient selection and toxicity monitoring.
Association between intratumoral Fusobacterium nucleatum levels and clinical outcomes in esophageal squamous cell carcinoma: A comprehensive systematic review.
Vel, Adarsh, Mariappan, Tejaswin , Radhakrishnan, Pranav Krishna, S, Noorul Hidhaya, Srinivasan, Gurunathan, Kamaraj, Balakrishnan, Nagarajan, Hrithik Dakssesh Putta, Ganesan, Subash, Ritvika, Kalidindi, Velusamy, Breethiga, Saravanan, Shivani, Mohanraj, Aswin Prabhu, Sundararajan, Sakthibalan, S, Noorul Hidhaya, Srinivasan, Gurunathan, Kamaraj, Balakrishnan , Nagarajan, Hrithik Dakssesh Putta

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e16081 Get It

e16081 Background: Intratumoral Fusobacterium nucleatum (F. nuc) is a key microbial participant in gastrointestinal malignancy progression. In esophageal squamous cell carcinoma (ESCC), the link between bacterial colonization and metastatic potential requires characterization. This systematic review synthesizes evidence from independent cohorts to define the relationship between bacterial DNA load, molecular pathways driving metastasis, and survival. Methods: PubMed, EMBASE, and Cochrane databases were searched for studies till January 2026 evaluating F. nuc and ESCC prognosis using quantitative DNA-based assays (qPCR or 16S rRNA sequencing). Multivariate-adjusted hazard ratios (HR) for cancer-specific survival (CSS) and disease recurrence were pooled using a Random Effects Model; heterogeneity was assessed by I^2. Synthesis identified technical/geographic consistencies and correlations with pathological markers of tumor invasion and lymph node spread. Results: Eight studies from China and Japan met inclusion criteria. High intratumoral F. nuc load was a significant independent prognostic factor. Elevated DNA load was a robust predictor of poor outcomes, specifically associated with a CSS HR of 1.78 (95% CI 1.06-2.65). Recurrence risk was similarly elevated, yielding a pooled Relapse-Free Survival (RFS) HR of 1.71 (95% CI 1.27-2.30,I^2 = 0).Findings remained stable across multicenter registries in Japan and China, likely due to standardized qPCR targeting nusG or 16S rRNA genes. Qualitatively, high DNA load correlated with advanced pT stage and lymph node metastasis. This phenotype is mediated by TLR4/NF-κB and NOD1/RIPK2 signaling, which drive epithelial-mesenchymal transition (EMT) and foster an immunosuppressive "cold" tumor microenvironment characterized by M2-like macrophage and regulatory T-cell recruitment. Conclusions: Intratumoral F. nuc DNA quantification identifies a high-risk biological subtype of ESCC. Consistency across regional cohorts indicates F. nuc is a universal driver of metastatic progression in squamous cell pathology. Standardized microbial DNA quantification may serve as a high-fidelity biomarker to refine risk stratification and guide microbiota-targeted neoadjuvant strategies to mitigate metastatic spread in ESCC.
Early circulating tumor DNA dynamics as a prognostic and predictive biomarker in solid tumors treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Saravanan, Shivani, Kamaraj, Balakrishnan, Srinivasan, Gurunathan, Velusamy, Breethiga, Vel, Adarsh, Radhakrishnan, Pranav Krishna, Mariappan, Tejaswin , S, Noorul Hidhaya, Sundararajan, Sakthibalan, Ganesan, Subash, Ritvika, Kalidindi, Kamaraj, Balakrishnan , Srinivasan, Gurunathan, S, Noorul Hidhaya, Sundararajan, Sakthibalan

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e15091 Get It

e15091 Background: Early identification of patients likely to benefit from immune checkpoint inhibitors (ICIs) remains a major challenge across solid tumors. Circulating tumor DNA (ctDNA) kinetics have emerged as a promising noninvasive biomarker, yet results across studies are heterogeneous. We conducted a systematic review and meta-analysis to evaluate the prognostic and predictive value of early ctDNA reduction in patients receiving ICIs. Methods: A systematic search of PubMed, Embase, Web of Science, and Cochrane Library was conducted from inception through March 2025 following PRISMA guidelines. Studies evaluating early ctDNA dynamics (≤8 weeks after ICI initiation) in adult patients with solid tumors were included. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate (ORR). Random-effects models were used to pool hazard ratios (HRs) and odds ratios (ORs). Heterogeneity was assessed using I² statistics, and publication bias was evaluated with funnel plots and Egger’s test. Results: A total of 27 studies encompassing 3,842 patients across lung, melanoma, breast, gastrointestinal, and genitourinary malignancies met inclusion criteria. Early ctDNA reduction (defined as ≥50–90% decline or complete clearance, study-specific) was associated with significantly improved PFS (pooled HR 0.45; 95% CI 0.38–0.53; I² = 41%) and OS (pooled HR 0.40; 95% CI 0.32–0.49; I² = 36%). Patients demonstrating early ctDNA reduction had a markedly higher ORR (pooled OR 4.92; 95% CI 3.71–6.53; I² = 29%). Subgroup analyses showed consistent benefit across tumor types and ICI regimens. Early ctDNA dynamics outperformed baseline PD-L1 expression and tumor mutational burden in predicting treatment response. No significant publication bias was detected. Conclusions: Early ctDNA kinetics are a robust, tumor-agnostic biomarker associated with improved survival and treatment response in patients receiving ICIs. These findings support the integration of ctDNA monitoring into early treatment assessment and clinical trial design. Prospective trials are warranted to validate ctDNA-guided immunotherapy strategies.
Living liver donor safety: Intraoperative considerations in living liver donation—Guidelines from the ILTS–iLDLT group consensus conference 2025
Bhangui, Prashant , Hakeem, Abdul Rahman , Maira, Tommaso Di , Rammohan, Ashwin, Sayed, Blayne A. , Soejima, Yuji , Shingina, Alexandra , Cheah, Yee Lee , McCluskey, Stuart, Spiro, Michael , Ganesh, Swaytha , Rajalingam, Rajesh , Gupta, Subash , Findlay, James Y. , Chieh, Alfred Kow Wei, Sakamoto, Seisuko, Xia, Qiang, Kim, Ki-Hun , Polak, W., Soin, A G, Pomposelli, James J. , Vyas, Mary, Wiggins, Chantal, Mas, Valeria, Taner, Timucin, Broering, Dieter, Chen, Chao-Leng, Burra, Patrizia, Ascher, N. L., Lerut, Jan, Rela, Mohamed, Selzner, Nazia, Balci, Deniz, Olthoff, Kim M. , Polak, Wojciech G. , Hakeem, Abdul , Rammohan, Ashwin , Sayed, Blayne A , McCluskey, Stuart , Findlay, James, Sakamoto, Seisuko , Xia, Qiang , Polak, Wojciech G , Sapisochin, Gonzalo , Pomposelli, James , Selzner, Nazia , Balci, Deniz , Bhangui, Prashant , Di Maira, Tommaso , Gupta, Amar C. , Xia, Qiang , Sapisochín, Gonzalo , Soin, Arvinder S., Taner, Timuçin , Bröering, Dieter C. , Terrault, Norah A. , Burra, Patrizia , Hirschfield, Gideon M. , Lerut, Jan , Rela, Mohamed , Heimbach, Julie K. , Selzner, Nazia

Mayo Clinic

Liver Transplantation | January 5, 2026 | Volume: 32 | Issue: 4 | Pages: 592-608

10.1097/lvt.0000000000000800 | PMID 41490582 Get It

The success of living donor liver transplantation (LDLT) has bridged the growing gap between organ demand and availability in patients with liver failure or liver cancer. Safety of the living liver donor (LLD) is paramount, and astute intraoperative management plays a critical role in ensuring optimal outcomes for them. Given that intraoperative surgical and anesthesia practices vary widely across centers, the International Liver Transplantation Society (ILTS) and the International Living Donor Liver Transplantation Group (iLDLT Group) convened a global consensus conference in Toronto in March 2025 to develop guidelines for intraoperative management of the LLD. This manuscript details the recommendations on intraoperative considerations for the safety of LLD developed by Working Group II of the Consensus Scientific Committee, using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus. Working Group II focused on intraoperative monitoring, fluid and ventilation strategies, surgical techniques for vascular and biliary division, surgeon and center-specific experience, and intraoperative crises planning. These guidelines aim to support both established and emerging LDLT teams to ensure high-quality and safe intraoperative care for the LLD.
Global and regional mortality statistics of nipah virus from 1994 to 2023: a comprehensive systematic review and meta-analysis
Vasudevan, Srivatsa Surya , Subash, Arun, Mehta, Fena, Kandrikar, Tiba Yamin , Khan, Kaif, Khanduja, S., Raavi, Lekhya , Gondaliya, Piyush , Subash, Arun, Desai, Rupak , Khanduja, Sneha, Pitliya, Aakanksha , Kanagala, Sai Gautham

Mayo Clinic

Pathogens and Global Health | July 20, 2024 | Volume: 118 | Issue: 6 | Pages: 471-480

10.1080/20477724.2024.2380131 | PMID 39030703 Get It

A deep learning–enabled workflow to estimate real world progression-free survival in patients with metastatic breast cancer.
Varma, Gowtham , Yenukoti, Rohit K. , Ashrit, Bandlamudi Sai , Purushotham, K, Subash, C , Ravi, Sunil Kumar , Kurien, V.A., Aman, Avinash , Manoharan, Mithun , Jaiswal, Shashank , Anand, Akash , Barve, Rakesh , Thiagarajan, Viswanathan , Kumar, Praveen M , Kurien, Verghese, Lenehan, Patrick J. , Soefje, Scott A. , Soundararajan, Venky

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11176-11176

10.1200/jco.2024.42.16_suppl.11176 Get It

11176 Background: Progression-free survival (PFS) is frequently measured in oncology clinical trials. In analyses outside of the trial setting, various strategies have been utilized to assess real-world PFS (rwPFS), including manual abstraction of clinical records, natural language processing (NLP) of oncology notes and radiology reports, and longitudinal analyses of radiologic images. Here we develop and validate a new semi-automated workflow that combines NLP of clinical notes with structured electronic health record data to facilitate the evaluation of rwPFS in patients with metastatic breast cancer (mBC). Methods: This study analyzes de-identified EHR data using nference nSights. The data is extracted following privacy-preserving protocols and is HIPAA compliant. The overall cohort included 316 patients with HR-positive, HER2-negative mBC who initiated Palbociclib and Letrozole combination therapy between January 1, 2015 and December 31, 2021. We developed and implemented an ensemble of deep-learning NLP frameworks to capture progression events from unstructured clinical notes and radiology reports. A change in the line of therapy, as determined by structured drug order/administration records, was also considered a progression event. We used manually curated “ground-truth” datasets to evaluate the performance of the progression-event capture workflow at the levels of both sentences (N = 1000) and patients (N = 100) by calculating sensitivity, specificity, precision, accuracy, and F1 scores. Progression events and censoring events (death, loss to follow-up, end of study period) were considered to compute rwPFS. Results: At the sentence level, progression events were captured from clinical notes and radiology reports with a sensitivity of 99.8%, specificity of 96.7%, and accuracy of 98.2% (Table). At the patient level, initial progression was correctly captured within a window of +/-30 days with a sensitivity of 92.5%, specificity of 83.0%, and accuracy of 88.0% (Table). In a sample of 100 patients, the median rwPFS was determined to be 25 months (95% CI; 15-35 months) by manual curation and 22 months (95% CI; 15-35 months) by the semi-automated workflow. In the overall cohort, median rwPFS was 20 months (95% CI; 18-25 months). Conclusions: An ensemble of NLP algorithms extracted progression events from clinical notes and radiology reports with high accuracy. A semi-automated workflow enabled rapid and accurate determination of rwPFS in mBC patients receiving a combination chemotherapy regimen. Further evaluation of this workflow to estimate rwPFS in other cancers and therapeutic settings is warranted. [Table: see text]
Usability and Performance Comparison of Active Shape Memory and Passive Stockings for Medical Compression
Pettys‐Baker, Robert, Subash, Niharikha , Abel, Julianna , Shah, Surbhi , Holschuh, Brad

Mayo Clinic

Journal of Medical Devices | May 7, 2024 | Volume: 18 | Issue: 2 | Pages: No page available

10.1115/1.4065480 Get It

Abstract On-body compressive therapy is an essential treatment for a variety of health conditions. Traditional compression methods like pneumatics and knit stockings offer quality compression, but present issues with user experience (donning/doffing challenges or bulk/mass issues). This paper covers two studies related to active compression stockings, which utilize knitted shape memory alloy (SMA) wire to produce dynamic compression forces on the body. When these SMA knit panels are heated with an at-home heating pad, the knit contracts and creates dynamic compression. The first study characterizes the forces produced on the body by a new iteration of an SMA knit stocking. The second study compares two versions of the SMA knit garment with a commercially available knit compression garment. The results show that SMA knit compression garments are able to produce medical grade compression on the body, but that sizing and material properties can greatly impact the forces produced. In a comparison of different compression stockings, the user experience of the SMA compression garment was preferred over the alternative garments. Overall, the potential of SMA knit compression is further highlighted, with a clear need for further development to ensure consistent medical grade compression.
Wearability and Comfort Improvements to Active Compression Stockings for Lower Leg Compressive Therapy
Pettys‐Baker, Robert, Subash, Niharikha , Clarke, Megan , Shah, Surbhi , Abel, Julianna , Holschuh, Brad , Granberry, Rachael , Woelfle, Heidi

Mayo Clinic

Proceedings of the 2022 ACM International Symposium on Wearable Computers | December 27, 2022 | Volume: No volume available | Issue: No issue available | Pages: 127-130

10.1145/3544794.3560812 Get It

Characterizing the Effects of Annealing Temperature on Knitted Shape Memory Actuators
Pettys‐Baker, Robert, Subash, Niharikha , Mack, Isidora, Shah, Surbhi , Abel, Julianna , Holschuh, Brad

Mayo Clinic

ASME 2022 Conference on Smart Materials, Adaptive Structures and Intelligent Systems | November 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/smasis2022-90779 Get It

Abstract Advancements in the design of knitted Shape Memory Alloy (SMA) actuators have produced highly functional and easy-to-wear advanced textiles with variable fit/stiffness properties. Annealing SMA at high temperatures can alter their thermomechanical properties; however, heat treatments of SMA knitted actuators have yet to be systematically studied. This study investigates the relationship between annealing temperatures and the resultant SMA knit thermomechanical behavior (maximum force and actuator transformation temperature). Twelve SMA knitted samples were manufactured using Dynalloy Flexinol® 70°C (0.012″). Nine samples were annealed at three different temperatures (350°C, 450°C, 550°C), with the remaining samples acting as controls. The blocked force mechanical performance was characterized by varying the thermal load across various applied structural strains. The samples were thermally cycled between 20°C and 90°C at each strain level. The results indicate that samples annealed while stretched along the knit-course direction enabled large-force actuation at smaller displacements than the control samples. Annealed samples showed higher peak force than control samples as annealing temperature increased until the 450°C condition; however, the 550° samples showed a dip in force. The actuator transformation temperatures showed reduced Austenite start (As) temperature compared to the control sample, enabling actuation at a lower temperature while also reducing the Martensite Finish (Mf) temperatures. This work allows for greater tuning of knitted SMA actuators to meet the needs of researchers and product developers.
Transoral Robotic Surgery for Recurrent Tumors of the Upper Aerodigestive Tract (RECUT): An International Cohort Study
Hardman, John , Holsinger, F. Christopher , Brady, Grainne , Beharry, Avinash , Bonifer, Alec , D’Andréa, Grégoire , Dabas, Surender, Almeida, John R. de , Duvvuri, Umamaheswar , Floros, Peter , Ghanem, Tamer , Hamilton, David W. , Larsen, Mikkel Hjordt Holm , Magnuson, J. Scott , Miles, Brett A., Moore, Eric J. , Pantvaidya, Gouri , Rubek, Niclas , Simon, Christian , Abel, Kathryn M. Van , Poorten, Vincent Vander , Walgama, Evan , Greenlay, Emily, Potts, Laura, Balaji, Arun, Starmer, Heather M. , Stephen, S. , Roe, Justin , Harrington, Kevin J. , Paleri, Vinidh , Hardman, John C , Holsinger, F Chris , Brady, Grainne C , Bonifer, Alec T , de Almeida, John R , Ghanem, Tamer A , Gorphe, Philippe , Gross, Neil D , Hamilton, David , Kurukulasuriya, Chareeni , Larsen, Mikkel Hjordt Holm , Lin, Daniel J , Magnuson, J Scott , Meulemans, Jeroen , Miles, Brett A , Moore, Eric J , Pantvaidya, Gouri , Roof, Scott , Rubek, Niclas , Subash, Anand , Topf, Michael C , Van Abel, Kathryn M , Vander Poorten, Vincent , Walgama, Evan S , Greenlay, Emily , Potts, Laura , Balaji, Arun , Roe, Justin , Harrington, Kevin , Paleri, Vinidh , Topf, Michael C.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 9, 2022 | Volume: 114 | Issue: 10 | Pages: 1400-1409

10.1093/jnci/djac130 | PMID 35944904 Get It

Abstract Background Transoral robotic surgery (TORS) is an emerging minimally invasive surgical treatment for residual, recurrent, and new primary head and neck cancers in previously irradiated fields, with limited evidence for its oncological effectiveness. Methods A retrospective observational cohort study of consecutive cases performed in 16 high-volume international centers before August 2018 was conducted (registered at clinicaltrials.gov [NCT04673929] as the RECUT study). Overall survival (OS), disease-free survival, disease-specific survivals (DSS), and local control (LC) were calculated using Kaplan-Meier estimates, with subgroups compared using log-rank tests and Cox proportional hazards modeling for multivariable analysis. Maximally selected rank statistics determined the cut point for closest surgical resection margin based on LC. Results Data for 278 eligible patients were analyzed, with median follow-up of 38.5 months. Two-year and 5-year outcomes were 69.0% and 62.2% for LC, 71.8% and 49.8% for OS, 47.2% and 35.7% for disease-free survival, and 78.7% and 59.1% for disease-specific survivals. The most discriminating margin cut point was 1.0 mm; the 2-year LC was 80.9% above and 54.2% below or equal to 1.0 mm. Increasing age, current smoking, primary tumor classification, and narrow surgical margins (≤1.0 mm) were statistically significantly associated with lower OS. Hemorrhage with return to theater was seen in 8.1% (n = 22 of 272), and 30-day mortality was 1.8% (n = 5 of 272). At 1 year, 10.8% (n = 21 of 195) used tracheostomies, 33.8% (n = 66 of 195) used gastrostomies, and 66.3% (n = 53 of 80) had maintained or improved normalcy of diet scores. Conclusions Data from international centers show TORS to treat head and neck cancers in previously irradiated fields yields favorable outcomes for LC and survival. Where feasible, TORS should be considered the preferred surgical treatment in the salvage setting.